Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shengwei Mo

Showing results (11-20 of 31) with videos related to

Pageof 4
Sort By:
Archives of Pathology & Laboratory Medicine|January 20, 2023
B7-H4 Further Stratifies Patients With Endometrial Cancer Exhibiting a Nonspecific Molecular ProfileLiju Zong, Shuangni Yu, Shengwei Mo, et al.
Cancer Immunology, Immunotherapy : CII|April 9, 2020
Expression of the immune checkpoint VISTA in breast cancerLiju Zong, Shengwei Mo, Shuangni Yu, et al.
The Journal of Pathology. Clinical Research|January 17, 2022
PD-L1 and PD-L2 expression in pancreatic ductal adenocarcinoma and their correlation with immune infiltrates and DNA damage response moleculesYue Zhang, Xianlong Chen, Shengwei Mo, et al.
Neuroendocrinology|December 28, 2021
High Mast Cell Density Predicts a Favorable Prognosis in Patients with Pancreatic Neuroendocrine NeoplasmsShengwei Mo, Liju Zong, Xianlong Chen, et al.
The Journal of Pathology. Clinical Research|January 27, 2022
Analysis of a novel immune checkpoint, Siglec-15, in pancreatic ductal adenocarcinomaXianlong Chen, Shengwei Mo, Yue Zhang, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 21, 2020
High VISTA Expression Correlates With a Favorable Prognosis in Patients With Colorectal CancerLiju Zong, Shuangni Yu, Shengwei Mo, et al.
Gynecologic Oncology|July 17, 2021
PD-L1 expression in tumor cells is associated with a favorable prognosis in patients with high-risk endometrial cancerLiju Zong, Zezheng Sun, Shengwei Mo, et al.
Archives of Pathology & Laboratory Medicine|July 21, 2022
Prognostic Value of Programmed Death Ligand-1 in Discriminating Patients With Lymph Node-Negative, p53-Wild-Type, or Low-BRCA1/2-Expression Pancreatic Ductal AdenocarcinomaXianlong Chen, Yue Zhang, Shengwei Mo, et al.
Archives of Pathology & Laboratory Medicine|June 7, 2022
Expression and Prognostic Value of B7 Family Immune Checkpoints in Pancreatic Neuroendocrine TumorsShengwei Mo, Liju Zong, Xianlong Chen, et al.
Endocrine|February 10, 2024
The significance of an immunohistochemical marker-based panel in assisting the diagnosis of parathyroid carcinomaYa Hu, Shengwei Mo, Jinheng Xiao, et al.
Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
Archives of Pathology & Laboratory Medicine|January 20, 2023
B7-H4 Further Stratifies Patients With Endometrial Cancer Exhibiting a Nonspecific Molecular ProfileLiju Zong, Shuangni Yu, Shengwei Mo, et al.
Cancer Immunology, Immunotherapy : CII|April 9, 2020
Expression of the immune checkpoint VISTA in breast cancerLiju Zong, Shengwei Mo, Shuangni Yu, et al.
The Journal of Pathology. Clinical Research|January 17, 2022
PD-L1 and PD-L2 expression in pancreatic ductal adenocarcinoma and their correlation with immune infiltrates and DNA damage response moleculesYue Zhang, Xianlong Chen, Shengwei Mo, et al.
Neuroendocrinology|December 28, 2021
High Mast Cell Density Predicts a Favorable Prognosis in Patients with Pancreatic Neuroendocrine NeoplasmsShengwei Mo, Liju Zong, Xianlong Chen, et al.
The Journal of Pathology. Clinical Research|January 27, 2022
Analysis of a novel immune checkpoint, Siglec-15, in pancreatic ductal adenocarcinomaXianlong Chen, Shengwei Mo, Yue Zhang, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 21, 2020
High VISTA Expression Correlates With a Favorable Prognosis in Patients With Colorectal CancerLiju Zong, Shuangni Yu, Shengwei Mo, et al.
Gynecologic Oncology|July 17, 2021
PD-L1 expression in tumor cells is associated with a favorable prognosis in patients with high-risk endometrial cancerLiju Zong, Zezheng Sun, Shengwei Mo, et al.
Archives of Pathology & Laboratory Medicine|July 21, 2022
Prognostic Value of Programmed Death Ligand-1 in Discriminating Patients With Lymph Node-Negative, p53-Wild-Type, or Low-BRCA1/2-Expression Pancreatic Ductal AdenocarcinomaXianlong Chen, Yue Zhang, Shengwei Mo, et al.
Archives of Pathology & Laboratory Medicine|June 7, 2022
Expression and Prognostic Value of B7 Family Immune Checkpoints in Pancreatic Neuroendocrine TumorsShengwei Mo, Liju Zong, Xianlong Chen, et al.
Endocrine|February 10, 2024
The significance of an immunohistochemical marker-based panel in assisting the diagnosis of parathyroid carcinomaYa Hu, Shengwei Mo, Jinheng Xiao, et al.
Pageof 4